These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21877601)

  • 21. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of rabbit antithymocyte globulin and basiliximab induction.
    Brennan DC; Schnitzler MA
    N Engl J Med; 2008 Oct; 359(16):1736-8. PubMed ID: 18923181
    [No Abstract]   [Full Text] [Related]  

  • 23. A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients.
    Mariat C; Afiani A; Alamartine E; Thibaudin D; de Filippis JP; Berthoux F
    Transplant Proc; 2001; 33(7-8):3192-3. PubMed ID: 11750368
    [No Abstract]   [Full Text] [Related]  

  • 24. Induction therapy in renal transplant recipients: how convincing is the current evidence?
    Wagner SJ; Brennan DC
    Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients.
    Laftavi MR; Pankewycz O; Feng L; Said M; Patel S
    Immunol Invest; 2015; 44(4):373-84. PubMed ID: 25942348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of ATG vs. Basiliximab induction.
    Ulrich F; Niedzwiecki S; Pascher A; Kohler S; Weiss S; Fikatas P; Schumacher G; May G; Reinke P; Neuhaus P; Tullius SG; Pratschke J
    Eur J Clin Invest; 2011 Sep; 41(9):971-8. PubMed ID: 21382021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basiliximab: efficacy and safety evaluation in kidney transplantation.
    Ponticelli C
    Expert Opin Drug Saf; 2014 Mar; 13(3):373-81. PubMed ID: 24266670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction immunosuppression with basiliximab in heart transplantation.
    Chou NK; Wang SS; Chen YS; Yu HY; Chi NH; Wang CH; Ko WJ; Tsao CI; Sun CD
    Transplant Proc; 2008 Oct; 40(8):2623-5. PubMed ID: 18929820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up.
    Mangus RS; Fridell JA; Vianna RM; Kwo PY; Chen J; Tector AJ
    Liver Transpl; 2012 Jul; 18(7):786-95. PubMed ID: 22237953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
    Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
    Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
    Gavela Martínez E; Avila Bernabeu AI; Sancho Calabuig A; Beltrán Catalán S; Escudero Quesada V; Pallardó Mateu LM
    Transplant Proc; 2009; 41(6):2337-8. PubMed ID: 19715913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithymocyte globulin versus basiliximab in renal transplantation.
    Killen JP; Chadban S
    N Engl J Med; 2007 Feb; 356(6):634; author reply 634-5. PubMed ID: 17287486
    [No Abstract]   [Full Text] [Related]  

  • 37. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
    van den Hoogen MW; Hoitsma AJ; Hilbrands LB
    Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunosuppressive treatments: mechanisms of action and clinical use].
    Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
    Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.